30-day readmission for Staph bacteremia patients is common, costs $12K+

A study published in Clinical Infectious Diseases examined outcomes for patients with methicillin-susceptible and-resistant Staphylococcus aureus bacteremia, particularly focusing on readmissions.

Advertisement

Researchers conducted a retrospective analysis using the 2014 Nationwide Readmissions Database, which captured 49.3 percent of U.S. hospitalizations. They identified MSSA and MRSA bacteremia among patients older than 18 years and included the results in their analysis.

Of 92,089 patients with S. aureus bacteremia, 48.5 percent had MRSA bacteremia. The 30-day readmission rate was 22 percent overall.

Patients with MRSA bacteremia experienced an increased likelihood of readmission for:

• Bacteremia recurrence
• Higher in-hospital mortality
• Longer hospitalization

The cost of readmission was $12,425 per case overall.

More articles on healthcare quality:
Former CDC leader on bird flu threat: ‘We don’t know how the story’s going to end’
Health experts urge Facebook to crack down on anti-vaccine groups
Hospitals send many patients home with ‘risky’ antibiotics, study finds

Advertisement

Next Up in Clinical Leadership & Infection Control

Advertisement

Comments are closed.